Patents by Inventor Stanley N. Cohen

Stanley N. Cohen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10945954
    Abstract: The invention provide isolated arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicles (ARMMs). Methods for generating and for isolating ARMMs are also provided herein. ARMMs can be used to deliver agents, for example, nucleic acids (e.g., siRNAs, microRNAs, lincRNAs), proteins (e.g., transcription factors, chromatin modulators, kinases, phosphorylases, or recombinases), or small molecules to target cells in vitro and in vivo, and methods for such ARMM-mediated delivery are provided herein. Diagnostic and therapeutic methods using ARMMs are also described herein.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: March 16, 2021
    Assignees: President and Fellows of Harvard College, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Quan Lu, Joseph F. Nabhan, Stanley N. Cohen
  • Publication number: 20210040479
    Abstract: The present invention provides a method of modulating the expression of a gene containing expanded nucleotide repeats in a cell, comprising: inhibiting the biological activity of SPT4 or SUPT4H; and regulating the formation of R-loops. The inhibition step can effectively reduce the expression of the gene containing the expanded nucleotide repeats and the regulatory step can further enhance the inhibition step. The inhibition step and the regulation step are for the purpose of regulating gene expression by interfering the capacity of RNA polymerase II transcribing over a DNA template with lengthy nucleotide repeats.
    Type: Application
    Filed: January 22, 2019
    Publication date: February 11, 2021
    Inventors: Tzu-Hao CHENG, Chia-Rung LIU, Tse-I LIN, Yun-Yun WU, Stanley N. COHEN
  • Patent number: 10882821
    Abstract: Aspects of the present disclosure include methods of reducing the deleterious impact of a target gene in a cell, such as the deleterious activity of a mutant extended nucleotide repeat (NR) containing target gene in a cell, by contacting the cell with an effective amount of an enantiomeric tetrahydrocarbazolamine compound. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended NR containing target gene may be reduced, e.g., by reducing (and in some instances differentially, including selectively, reducing) the production or activity of toxic expression products (e.g., RNA or protein) encoded by the target gene. Kits and compositions for practicing the subject methods are also provided.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: January 5, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Stanley N. Cohen, Ning Deng
  • Patent number: 10760077
    Abstract: Aspects of the invention include methods of selectively reducing the deleterious activity of mutant extended trinucleotide repeat containing genes in a cell, as well as compositions used in such methods. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended trinucleotide repeat containing gene may be selectively reduced in a variety of different ways, e.g., by selectively decreasing SPT4 mediated transcriptional activity, by enhancing functionality of proteins encoded thereby, etc. Aspects of the invention further include assays for identifying agents that find use in methods of the invention, e.g. as summarized above. Methods and compositions of the invention find use in a variety of different applications, including the prevention or treatment of disease conditions associated with the presence of genes containing mutant extended trinucleotide repeats, such as Huntington's Disease (HD).
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: September 1, 2020
    Assignees: The Board of Trustees of the Leland Stanford Junior University, National Yang-Ming University
    Inventors: Tzu-Hao Cheng, Chia-Rung Liu, Tzu-Han Wang, Stanley N. Cohen
  • Patent number: 10675293
    Abstract: Aspects of the invention include methods of reducing the deleterious activity of a mutant extended nucleotide repeat (NR) containing target gene in a cell by contacting the cell with an effective amount of a nucleoside agent, as well as compositions used in such methods. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended NR containing target gene may be reduced in a variety of different ways, e.g., by reducing (and in some instances differentially, including selectively, reducing) the production or activity of toxic expression products (e.g., RNA or protein) encoded by the target gene. Kits and compositions for practicing the subject methods are also provided.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: June 9, 2020
    Assignees: The Board of Trustees of the Leland Stanford Junior University, National Yang-Ming University
    Inventors: Stanley N. Cohen, Ning Deng, Yanan Feng, Tzu-Hao Cheng, Yun-Yun Wu, Wen-Chieh Hsieh
  • Publication number: 20200147069
    Abstract: Aspects of the present disclosure include methods of reducing the deleterious impact of a target gene in a cell, such as the deleterious activity of a mutant extended nucleotide repeat (NR) containing target gene in a cell by contacting the cell with an effective amount of a tetrahydrocarbazolamine compound. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended NR containing target gene may be reduced, e.g., by reducing (and in some instances differentially, including selectively, reducing) the production or activity of toxic expression products (e.g., RNA or protein) encoded by the target gene. Kits and compositions for practicing the subject methods are also provided.
    Type: Application
    Filed: June 19, 2018
    Publication date: May 14, 2020
    Inventors: Stanley N. Cohen, Ning Deng, Yanan Feng, Tzu-Hao Cheng, Thomas W. Sun
  • Publication number: 20190241876
    Abstract: Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.
    Type: Application
    Filed: April 12, 2019
    Publication date: August 8, 2019
    Applicants: President and Fellows of Harvard College, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Quan Lu, Qiyu Wang, Stanley N. Cohen
  • Patent number: 10260055
    Abstract: Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of cargo proteins, such as transcription factors, tumor suppressors, developmental regulators, growth factors, metastasis suppressors, pro-apoptotic proteins, nucleases, recombinases, and reprogramming factors into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: April 16, 2019
    Assignees: President and Fellows of Harvard College, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Quan Lu, Qiyu Wang, Stanley N. Cohen
  • Publication number: 20180171336
    Abstract: Aspects of the invention include methods of selectively reducing the deleterious activity of mutant extended trinucleotide repeat containing genes in a cell, as well as compositions used in such methods. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended trinucleotide repeat containing gene may be selectively reduced in a variety of different ways, e.g., by selectively decreasing SPT4 mediated transcriptional activity, by enhancing functionality of proteins encoded thereby, etc. Aspects of the invention further include assays for identifying agents that find use in methods of the invention, e.g. as summarized above. Methods and compositions of the invention find use in a variety of different applications, including the prevention or treatment of disease conditions associated with the presence of genes containing mutant extended trinucleotide repeats, such as Huntington's Disease (HD).
    Type: Application
    Filed: December 6, 2017
    Publication date: June 21, 2018
    Inventors: Tzu-Hao Cheng, Chia-Rung Liu, Tzu-Han Wang, Stanley N. Cohen
  • Publication number: 20180119118
    Abstract: Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.
    Type: Application
    Filed: November 10, 2017
    Publication date: May 3, 2018
    Applicants: President and Fellows of Harvard College, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Quan Lu, Qiyu Wang, Stanley N. Cohen
  • Publication number: 20180064744
    Abstract: Aspects of the invention include methods of reducing the deleterious activity of a mutant extended nucleotide repeat (NR) containing target gene in a cell by contacting the cell with an effective amount of a nucleoside agent, as well as compositions used in such methods. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended NR containing target gene may be reduced in a variety of different ways, e.g., by reducing (and in some instances differentially, including selectively, reducing) the production or activity of toxic expression products (e.g., RNA or protein) encoded by the target gene. Kits and compositions for practicing the subject methods are also provided.
    Type: Application
    Filed: May 18, 2016
    Publication date: March 8, 2018
    Inventors: Stanley N. Cohen, Ning Deng, Yanan Feng, Tzu-Hao Cheng, Yun-Yun Wu, Wen-Chieh Hsieh
  • Publication number: 20180055768
    Abstract: The invention provide isolated arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicles (ARMMs). Methods for generating and for isolating ARMMs are also provided herein. ARMMs can be used to deliver agents, for example, nucleic acids (e.g., siRNAs, microRNAs, lincRNAs), proteins (e.g., transcription factors, chromatin modulators, kinases, phosphorylases, or recombinases), or small molecules to target cells in vitro and in vivo, and methods for such ARMM-mediated delivery are provided herein. Diagnostic and therapeutic methods using ARMMs are also described herein.
    Type: Application
    Filed: August 4, 2017
    Publication date: March 1, 2018
    Applicants: President and Fellows of Harvard College, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Quan Lu, Joseph F. Nabhan, Stanley N. Cohen
  • Patent number: 9862947
    Abstract: Aspects of the invention include methods of selectively reducing the deleterious activity of mutant extended trinucleotide repeat containing genes in a cell, as well as compositions used in such methods. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended trinucleotide repeat containing gene may be selectively reduced in a variety of different ways, e.g., by selectively decreasing SPT4 mediated transcriptional activity, by enhancing functionality of proteins encoded thereby, etc. Aspects of the invention further include assays for identifying agents that find use in methods of the invention, e.g. as summarized above. Methods and compositions of the invention find use in a variety of different applications, including the prevention or treatment of disease conditions associated with the presence of genes containing mutant extended trinucleotide repeats, such as Huntington's Disease (HD).
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: January 9, 2018
    Assignees: The Board of Trustees of the Leland Stanford Junior University, National Yang-Ming University
    Inventors: Tzu-Hao Cheng, Chia-Rung Liu, Tzu-Han Wang, Stanley N. Cohen
  • Patent number: 9816080
    Abstract: Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: November 14, 2017
    Assignees: President and Fellows of Harvard College, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Quan Lu, Qiyu Wang, Stanley N. Cohen
  • Patent number: 9737480
    Abstract: The invention provide isolated arrestin domain-containing protein 1 (ARRDC1)-mediated micro vesicles (ARMMs). Methods for generating and for isolating ARMMs are also provided herein. ARMMs can be used to deliver agents, for example, nucleic acids (e.g., siRNAs, microRNAs, lincRNAs), proteins (e.g., transcription factors, chromatin modulators, kinases, phosphorylases, or recombinases), or small molecules to target cells in vitro and in vivo, and methods for such ARMM-mediated delivery are provided herein. Diagnostic and therapeutic methods using ARMMs are also described herein.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: August 22, 2017
    Assignees: President and Fellows of Harvard College, The Board of Trustees of the Leland Standford Junior University
    Inventors: Quan Lu, Joseph F. Nabhan, Stanley N. Cohen
  • Patent number: 9637741
    Abstract: This invention provides a method for modulating the expression of a first gene in a cell wherein the first gene is one containing more than 36 CAG trinucleotide repeats and encoding a protein that form polyglutamine-mediated protein aggregation. Suppression of the first gene is achieved by reducing the expression of SPT4 gene or SUPT4H gene. It can also be achieved by inhibiting the formation of a Spt4/Spt5 complex or a Supt4h/Supt5h complex. Also provided is a method for identifying an agent useful for modulating the expression and aggregation of CAG-expanded gene product, or treating a polyglutamine disease such as Huntington's disease.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: May 2, 2017
    Assignees: National Yang Ming University, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Tzu-Hao Cheng, Chia-Rung Liu, Tzu-Han Wang, Stanley N. Cohen
  • Publication number: 20160206566
    Abstract: Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.
    Type: Application
    Filed: October 30, 2015
    Publication date: July 21, 2016
    Applicants: President and Fellows of Harvard College, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Quan Lu, Qiyu Wang, Stanley N. Cohen
  • Publication number: 20160152978
    Abstract: Aspects of the invention include methods of selectively reducing the deleterious activity of mutant extended trinucleotide repeat containing genes in a cell, as well as compositions used in such methods. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended trinucleotide repeat containing gene may be selectively reduced in a variety of different ways, e.g., by selectively decreasing SPT4 mediated transcriptional activity, by enhancing functionality of proteins encoded thereby, etc. Aspects of the invention further include assays for identifying agents that find use in methods of the invention, e.g. as summarized above. Methods and compositions of the invention find use in a variety of different applications, including the prevention or treatment of disease conditions associated with the presence of genes containing mutant extended trinucleotide repeats, such as Huntington's Disease (HD).
    Type: Application
    Filed: December 7, 2015
    Publication date: June 2, 2016
    Inventors: Tzu-Hao Cheng, Chia-Rung Liu, Tzu-Han Wang, Stanley N. Cohen
  • Publication number: 20160116456
    Abstract: This invention provides a method for modulating the expression of a first gene in a cell wherein the first gene is one containing more than 36 CAG trinucleotide repeats and encoding a protein that form polyglutamine-mediated protein aggregation. Suppression of the first gene is achieved by reducing the expression of SPT4 gene or SUPT4H gene. It can also be achieved by inhibiting the formation of a Spt4/Spt5 complex or a Supt4h/Supt5h complex. Also provided is a method for identifying an agent useful for modulating the expression and aggregation of CAG-expanded gene product, or treating a polyglutamine disease such as Huntington's disease.
    Type: Application
    Filed: December 2, 2015
    Publication date: April 28, 2016
    Inventors: Tzu-Hao Cheng, Chia-Rung Liu, Tzu-Han Wang, Stanley N. Cohen
  • Patent number: 9226935
    Abstract: This invention provides a method for modulating the expression of a first gene in a cell wherein the first gene is one containing more than 36 CAG trinucleotide repeats and encoding a protein that form polyglutamine-mediated protein aggregation. Suppression of the first gene is achieved by reducing the expression of SPT4 gene or SUPT4H gene. It can also be achieved by inhibiting the formation of a Spt4/Spt5 complex or a Supt4h/Supt5h complex. Also provided is a method for identifying an agent useful for modulating the expression and aggregation of CAG-expanded gene product, or treating a polyglutamine disease such as Huntington's disease.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: January 5, 2016
    Assignees: NATIONAL YANG MING UNIVERSITY, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Tzu-Hao Cheng, Chia-Rung Lu, Tzu-Han Wang, Stanley N. Cohen